
UCLA Broad Stem Cell Research Center/Stem Cell Reports
Human embryonic stem cell-derived neurons (green) showing nuclei in blue. Left: with retinoic acid added. Right: with retinoic acid and BMP4 added, creating proprioceptive sensory interneurons (pink).
Researchers are the first to create sensory interneurons from stem cells
Researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have, for the first time, coaxed human stem cells to become sensory interneurons — the cells that give us our sense of touch. The new protocol could be a step toward stem cell–based therapies to restore sensation in paralyzed people who have lost feeling in parts of their body.
The study, which was led by Samantha Butler, a UCLA associate professor of neurobiology and member of the Broad Stem Cell Research Center, was published today in the journal Stem Cell Reports.
Sensory interneurons, a class of neurons in the spinal cord, are responsible for relaying information from throughout the body to the central nervous system, which enables the sense of touch. The lack of a sense of touch greatly affects people who are paralyzed. For example, they often cannot feel the touch of another person, and the inability to feel pain leaves them susceptible to burns from inadvertent contact with a hot surface.
“The field has for a long time focused on making people walk again,” said Butler, the study’s senior author. “‘Making people feel again doesn’t have quite the same ring. But to walk, you need to be able to feel and to sense your body in space; the two processes really go hand in glove.”
In a separate study, published in September by the journal eLife, Butler and her colleagues discovered how signals from a family of proteins called bone morphogenetic proteins, or BMPs, influence the development of sensory interneurons in chicken embryos. The Stem Cell Reports research applies those findings to human stem cells in the lab.
When the researchers added a specific bone morphogenetic protein called BMP4, as well as another signaling molecule called retinoic acid, to human embryonic stem cells, they got a mixture of two types of sensory interneurons. DI1 sensory interneurons give people proprioception — a sense of where their body is in space — and dI3 sensory interneurons enable them to feel a sense of pressure.
The researchers found the identical mixture of sensory interneurons developed when they added the same signaling molecules to induced pluripotent stem cells, which are produced by reprogramming a patient’s own mature cells such as skin cells. This reprogramming method creates stem cells that can create any cell type while also maintaining the genetic code of the person they originated from. The ability to create sensory interneurons with a patient’s own reprogrammed cells holds significant potential for the creation of a cell-based treatment that restores the sense of touch without immune suppression.
Butler hopes to be able to create one type of interneuron at a time, which would make it easier to define the separate roles of each cell type and allow scientists to start the process of using these cells in clinical applications for people who are paralyzed. However, her research group has not yet identified how to make stem cells yield entirely dI1 or entirely dI3 cells — perhaps because another signaling pathway is involved, she said.
The researchers also have yet to determine the specific recipe of growth factors that would coax stem cells to create other types of sensory interneurons.
The group is currently implanting the new dI1 and dI3 sensory interneurons into the spinal cords of mice to understand whether the cells integrate into the nervous system and become fully functional. This is a critical step toward defining the clinical potential of the cells.
“This is a long path,” Butler said. “We haven’t solved how to restore touch but we’ve made a major first step by working out some of these protocols to create sensory interneurons.”
Learn more: UCLA scientists make cells that enable the sense of touch
The Latest on: Stem cell–based therapies
via Google News
The Latest on: Stem cell–based therapies
- Saint-Gobain Life Sciences Introduces Highly Efficient Cell Culture Bags for T Cell Expansionon February 24, 2021 at 7:33 am
Saint-Gobain Life Sciences, an industry leader in material science-based solutions for cell and gene therapy manufacturing, today launched a new cell culture bag designed specifically for T cell ...
- Metagenomi Announces the Addition of Leading Immuno-oncology Clinical Research Experts to its Scientific Advisory Boardon February 24, 2021 at 5:13 am
Metagenomi, a metagenomics powered gene editing and cell & gene therapy company, today announced the addition of three leading experts in immuno-oncology clinical and basic research from Fred ...
- JDRF announces new Center of Excellence in New England to advance type 1 diabetes researchon February 23, 2021 at 6:07 am
JDRF, the leading global organization funding type 1 diabetes (T1D) research, announces, in collaboration with the Harvard Stem Cell Institute, the launch of the JDRF Center of Excellence in New ...
- The global cell therapy market is expected to reach US$ 12,563.23 million by 2027 from US$ 7,260.50 million in 2019on February 23, 2021 at 4:03 am
Reportlinker.com announces the release of the report "Cell Therapy Market Forecast to 2027 - COVID-19 Impact and Global ...
- Identification of stem cells vital for hair regenerationon February 22, 2021 at 10:33 am
A new method for restoring hair growth, which uses stem cells, has been developed. The method, developed by a team of researchers at the RIKEN Centre for Biosystems Dynamics Research in Japan, used ...
- Therapeutic Solutions International Uses StemVacs(TM) Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cellson February 22, 2021 at 7:59 am
Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today novel data and filing of a patent application demonstrating that StemVacs™ cells carrying proprietary sequences from the ...
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Research Report by Manufacturers, Region, Type and Application, Forecast to 2026on February 22, 2021 at 5:08 am
Feb (Heraldkeepers) -- Autologous stem-cell transplantation (also called autogenetic, autogenic, or autogenic stem-cell transplantation or ...
- Reducing alcohol and/or cocaine-induced reward and toxicity via an epidermal stem cell-based gene delivery platformon February 21, 2021 at 4:00 pm
Alcohol use disorder (AUD) is one of the foremost public health problems. Alcohol is also frequently co-abused with cocaine. There is a huge unmet need for the treatment of AUD and/or cocaine co-abuse ...
- Human induced pluripotent stem cell-based platform for modeling cardiac ischemiaon February 18, 2021 at 2:16 pm
Many therapeutics that have been promising in animal models have failed in human trials. Thus, functional human based cardiac ischemia models are required. In this study, a human induced pluripotent ...
- Lab-grown 'mini-bile ducts' used to repair human livers in regenerative medicine firston February 18, 2021 at 11:05 am
Scientists have used a technique to grow bile duct organoids—often referred to as 'mini-organs' - in the lab and shown that these can be used to repair damaged human livers. This is the first time ...
via Bing News